Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused ...
Fewer jabs GSK shares fell owing to a “disappointing” demand for its vaccines during the third quarter of this year. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback